JERSEY, Channel Islands, April 16, 2015 (GLOBE NEWSWIRE) -- Quotient Limited (Nasdaq:QTNT), a commercial-stage diagnostics company, today announced the launch of two new products to expand its reagent red cell product offering following licensure by the U.S. Food and Drug Administration.
The two new products are:
- ALBAsure® QC Kit
- ALBAcyte® C3 Coated Red Blood Cells
"With the introduction of these two exciting new products, Quotient adds to one of the most comprehensive reagent red cell product offerings in the industry," said Jeremy Stackawitz, President of Quotient. "We continue to provide innovative, high-quality products at low cost, in combination with superior customer support, creating unparalleled value for our customers."
The ALBAsure® QC Kit is a qualitative control used to evaluate ABO, RhD and antibody screening reagents by manual blood grouping methods. It allows blood bank laboratories to confirm the reactivity and performance of routinely used reagents on each day of use.
The ALBAcyte® C3 Coated Red Blood Cells are used as a control to confirm the presence or absence of Anti-C3 reactivity of Anti-Human Globulin (AHG) reagent and as indicator cells in AHG testing.
The new products will be available for purchase and sampling beginning in May of 2015.
About Quotient Limited
Quotient Limited (Quotient) is an established, commercial-stage diagnostics company committed to reducing healthcare costs and improving patient care through the development and commercialization of innovative tests, currently focused on blood grouping and serological disease screening. Quotient is developing its proprietary MosaiQTM technology platform to offer a breadth of tests that is unmatched by any commercially available transfusion diagnostic instrument platform. The company's operations are based in Edinburgh, Scotland; Newtown, Pennsylvania; and Eysins, Switzerland.